IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc.'s Q·Score is 7.8/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 74% return on equity and 25% profit margins. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for IDXX is $698.92, based on ratings from 13 Wall Street analysts. This is 36.8% above the current price of $510.73. Price targets are forward-looking estimates and not guarantees of future performance.

IDEXX Laboratories, Inc. (IDXX) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 30.5×. The consensus analyst price target of $698.92 is 37% above the current price.

IDEXX Laboratories, Inc.'s next earnings report is expected on approximately November 2, 2026.

IDEXX Laboratories, Inc. has a net profit margin of 25.0%, which is considered high and reflects strong pricing power. Its gross margin stands at 62.4%, indicating a high-margin business model.

IDEXX Laboratories, Inc. is reporting modest revenue growth of 9.7%. Earnings are also growing at 17.6%, indicating improving profitability.

IDEXX Laboratories, Inc. has a debt-to-equity ratio of 0.68×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.17×, suggesting it should be monitored for near-term liquidity.